Is the “new normal” our window of opportunity to improve policy-making processes?
The health policy goalposts have moved again and, this time, we have an opportunity to make the world a better, more equitable place! Most countries abandoned the “Zero COVID” target long ago, and we are now gradually shifting from a pandemic (“public health emergency”) status to our “new normal”, as we learn to live with SARS-CoV-2 as an endemic virus.
Expert consensus is that this shift will occur when total respiratory viral infections, hospitalizations, and deaths inclusive of those from COVID-19 are no higher than what typically occurred in the most severe influenza years before the current pandemic.
The Journal of the American Medical Association (JAMA) recently published a series of articles, including A National Strategy for the “New Normal” of Life With COVID, in which former advisers to U.S. President Biden propose a new plan1 and detailed set of strategies for testing, surveillance, and mitigation2, as well as vaccines and therapeutics3.
Here at Policy Wisdom, we like to ask, “what does that mean for global health?” and “what are the policy opportunities?” a lot! So, we have dedicated this newsletter to considering these recommendations from a global perspective, since the need for such a plan extends well beyond the U.S. We also consider which key issues represent a policy opportunity.
Recommendations put forth in the JAMA series of articles include:
TESTING, SURVEILLANCE, AND MITIGATION
- Low-cost and accessible testing
- Voucher program for accessing N95 and KN95 masks
- Bolstered public health work force
- Paid sick and family medical leave for all U.S. workers
- Vaccine mandates
- System for clear recommendations from trusted public health authorities
- Improved air and wastewater surveillance and genomic sequencing
- Comprehensive genomic surveillance system for variants
- Real-time, opt-out digital surveillance system to monitor all vaccinated individuals
VACCINES AND THERAPEUTICS
- Research into optimal vaccination strategies
- Alternative vaccine administration mechanisms
- Investment in variant-specific vaccines
- Accelerated efforts to develop a universal coronavirus vaccine
- Faster development and more efficient deployment of vaccines and therapeutics
- Rapid development of efficacious oral antiviral treatments
The authors also state five requirements to cope with pandemic, and eventually, endemic SARS-CoV-2 and to respond to future public health threats. These are:
- Deploying real-time information systems
- Public health implementation workforce
- Flexible health systems
- Trust in government and public health institutions
- Belief in the value of collective action for public good
This is a tall order, due to the substantial resources required, and current attitudes and events signaling continued opposition to mass COVID vaccination and other mitigation measures, along with distrust in decision-makers.
How can the current situation be turned into an opportunity to enable better health policies and better policy-making processes?
What role can the government, NGOs, and the private sector play to help address key issues?
Key issues to manage from a policy perspective

The following table offers a sampling of “conversation starters” on a range of policy opportunities and roles for key stakeholder groups that stem from the lessons learned during the pandemic.
KEY ISSUES
Foster motivation and trust

GOVERNMENT: Promote guidelines and standards for continuous monitoring, evaluation and reporting of public perceptions and community tolerance for different types of government decisions, policies, and mandates.
NGOs: Create a comprehensive framework for cross-pollinating global, regional, and national campaigns to increase trust in authorities and improve vaccine confidence.
PRIVATE SECTOR: Build a universal, publicly available platform and reporting structure for all vaccine and therapeutics manufacturers on product developments, safety data, and adverse events.
Redefine investment in health

GOVERNMENT: Introduce legislation to assess current health spending and commit to future spending targets that can sufficiently manage co-existence of chronic and infectious diseases, as well as the health consequences of environmental threats.
NGOs: Provide mechanisms for accurate, evidence-based forecasting, planning, and allocation of financial and workforce resources.
PRIVATE SECTOR: Inform development of healthcare investment policies via horizon scanning and other tools to support governments in forward-looking fiscal planning.
Build healthcare crisis reserves

GOVERNMENT: Implement a national framework for education, training, and financial incentives in order to bolster the healthcare workforce and encourage participation in crisis reserves.
NGOs: Prepare guidance and protocols to build and replenish workforce reserves (emulating the military reserves) in healthcare, education, and other key sectors that can be deployed as part of a crisis response.
PRIVATE SECTOR: Sponsor educational grants, training courses and other professional development programs to stimulate interest in public health and healthcare careers.
Ensure successful deployment for health

GOVERNMENT: Establish a central clearinghouse for stockpiling and fair and equitable access to essential pandemic supplies.
NGOs: Create a multi-sectoral consortium to develop an Essential Pandemic Services List modelled after the WHO Essential Medicines List.
PRIVATE SECTOR: Engage in agreements to provide products, services, technical expertise, and funding to facilitate distribution of essential pandemic resources.
Create a universal healthcare guideline

GOVERNMENT: Introduce legislation to extend or permanently adopt any temporary Public Health Emergency policies that proved successful during the pandemic.
NGOs: Recommend quality measures and metrics for creating, monitoring, and evaluating a universal
healthcare guideline that is modelled after clinical practice guidelines.
PRIVATE SECTOR: Compile and assess pandemic key learnings and best practices globally in order to support development of a universal healthcare guideline.
Reframe the concept of health equity

GOVERNMENT: Implement policy reforms to enable frameworks and standards that will achieve sustainable, system-wide equity.
NGOs: Create and launch a health equity scorecard to assist governments in monitoring and measuring a standardized set of indicators.
PRIVATE SECTOR: Collaborate with the global community on initiatives to advance health equity and social well-being.
So, what does this look like in practice?
First, we must truly ensure that transparency, engagement, and accountability is built into all policy-making processes, so that society can trust the policies being put in place to protect them. Without trust between all parties, none of this works.
Our “new normal” creates an opportunity to redefine success and reconnect disparate stakeholders, including the private sector, NGOs, international organizations, and governments.
Whether you represent a government agency, international organization, industry association, pharma company, or other private sector business, we welcome the opportunity to advance the conversation on how we can partner to develop innovative responses to these multifaceted, far-reaching issues.
How can Policy Wisdom support these efforts?

We are perfectly positioned as a neutral bridge connecting all sectors to act as a collective driving force for systemic change.

We are passionate public health experts who specialize in policy and communication with policy makers. We help all sides to listen better, respond more effectively, and act in the best interests of public health.

We are results-oriented and can help you shift from wanting to be a better partner in public health to being a true partner in public health.
References: 1 Emanuel EJ, Osterholm M, Gounder CR. (2022). A National Strategy for the “New Normal” of Life With COVID. JAMA. Accessed 15 February 2022 from: https://jamanetwork.com/journals/jama/article-abstract/2787944 2 Michaels D, Emanuel EJ, Bright RA. (2022). A National Strategy for COVID-19: Testing, Surveillance, and Mitigation Strategies. JAMA. Accessed 15 February 2022 from: https://jamanetwork.com/journals/jama/article-abstract/2787945 3 Borio LL, Bright RA, Emanuel EJ. (2022). A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics. JAMA. Accessed 15 February 2022 from: https://jamanetwork.com/journals/jama/article-abstract/2787946